Across TCGA pan-cancer cohorts, OR13J1 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated OR13J1 data layer compared with 21 for mass-spec protein.
The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher OR13J1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR13J1 expression acts as an unfavorable survival marker.
LUSC are the cancer types where OR13J1 Mutation most reproducibly stratifies survival.